A novel approach involves the use of FSH receptor-mediated nanocarriers for in vivo delivery of PDK2 shRNA, leveraging the FSH receptor's specific expression in ovaries as a targeting site for ovarian cancer. Here, FSHR is linked to ovarian cancer.